Exploring Prognostic Biomarkers in Lung Adenocarcinoma: Strategic Integration of Metabolic Subtyping and Ubiquitination Pathways

Read full text Summarise with VIRAT
Authors: Yang Yang, Jun Ho Yang, Deyang Liu, Xiaolu Fang, Baishan Liu
Cited by: 0
References: 47

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background Lung adenocarcinoma (LUAD), the most prevalent form of nonsmall cell lung cancer, poses significant diagnostic and therapeutic challenges due to its high mortality rate and complex pathophysiology. Despite advances in understanding LUAD’s molecular underpinnings, existing biomarkers are insufficient for personalized treatment, highlighting a critical need for innovative diagnostic and prognostic tools. Method By systematically analyzing data from the TCGA database, we identified three distinct metabolic subtypes of LUAD and conducted in‐depth metabolic and immune profiling on these metabolic subtypes. This study employs extensive bioinformatics methodologies, including weighted gene co‐expression network analysis (WGCNA) and least absolute shrinkage and selection operator (LASSO) regression, to discover and validate key genetic markers that impact LUAD prognosis. Results Our findings indicate that specific genes, such as SELK, C4orf27, PRDM2, FOSL2, and CHCHD4, play crucial roles in LUAD progression by intricately regulating ubiquitination pathways vital to tumor behavior. These genes are instrumental in orchestrating the delicate balance between ubiquitination and deubiquitination, essential for maintaining cellular homeostasis and regulating protein degradation pathways critical in oncogenesis. Notably, these genes exhibit a strong correlation with poor survival outcomes, highlighting their potential as therapeutic targets. Conclusions The unique value of this research lies in the novel integration of metabolic, immune, and genomic data to elucidate LUAD’s heterogeneity. By pinpointing critical genetic drivers of LUAD and their broader biological impacts, this study significantly enhances our capability to predict and alter the disease’s trajectory, ultimately paving the way for advancements in targeted therapies.

Fields of Study & Subjects

Lung Cancer Research Studies Ferroptosis and cancer prognosis Lung Cancer Treatments and Mutations

Publication details

Journal / source
International Journal of Genomics
Volume
2026
Issue
1
Pages
5660376
Publication date
1 January 2026
Language
EN